Drug profile · INN
tazarotene
TAZAROTENE
tazarotene (TAZAROTENE) is a retinoic acid receptor agonist. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
Drug details — tazarotene
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 20
- Programs
- 2
- Data quality
- 0.89
Quick answer
tazarotene (TAZAROTENE) is a retinoic acid receptor agonist. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Retinoic acid receptor agonist
Primary target: Retinoic acid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12065479
Force sensor cleavage domain containing chimeric polypeptides and methods of use thereof
granted -
US 11979133
Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
granted -
US 11920169
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11608492
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11331332
Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (SCAP) inhibitors
granted -
US 11311574
Methods and compositions for targeted cleavage and recombination
granted -
US 11206005
Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
granted -
US 11149321
Methods and compositions for targeted single-stranded cleavage and targeted integration
granted -
US 11071727
Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
granted -
US 11041174
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10941200
TREM2 cleavage modulators and uses thereof
granted -
US 10822599
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10729767
Humanized anti-C1s antibodies and methods of inhibiting C1s cleavage
granted -
US 10724020
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10689717
Methods and compositions for targeted single-stranded cleavage and targeted integration
granted -
US 10675302
Methods and compositions for targeted cleavage and recombination
granted -
US 10538787
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 10513549
Cleavage-activatable interferon-alpha proprotein
granted -
US 10291197
Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites and methods of use thereof
granted -
US 10113207
Methods and compositions for targeted single-stranded cleavage and targeted integration
granted
Frequently asked questions
What is tazarotene?
tazarotene (TAZAROTENE) is a retinoic acid receptor agonist. Associated with Almirall, S.A.. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for tazarotene?
TAZAROTENE is a marketed brand name for tazarotene. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tazarotene?
tazarotene has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.